anti cancer medicine

Pomired 4 mg Capsule (Pomalidomide): Potent Immunotherapy for Advanced Multiple Myeloma Pomired 4 mg Capsule is a high-efficacy anti-cancer medication featuring the active pharmaceutical ingredient Pomalidomide. Developed by Dr. Reddy’s Laboratories, Pomired belongs to the class of immunomodulatory agents (IMiDs). It is specifically engineered to treat adult patients with multiple myeloma who have exhausted other lines of therapy. As a third-generation thalidomide analogue, it offers enhanced potency and a targeted approach to destroying malignant plasma cells. Therapeutic Indications and Clinical Usage Pomired 4 mg is a vital component in modern oncology for: Relapsed and Refractory Multiple Myeloma (RRMM): Indicated for patients who have received at least two prior therapies, including both Lenalidomide and a proteasome inhibitor (such as Bortezomib), and have demonstrated disease progression. Combination Therapy: For optimal results, Pomired is usually prescribed in combination with low-dose Dexamethasone. Kaposi Sarcoma: In specific clinical scenarios, it is used to treat AIDS-related Kaposi Sarcoma or in patients who are HIV-negative. Mechanism of Action: How Pomired 4mg Works Pomired works through a multi-dimensional attack on cancer cells: Direct Tumor Inhibition: It targets the Cereblon (CRBN) protein, leading to the degradation of transcription factors essential for myeloma cell survival. This triggers apoptosis (programmed cell death). Immune System Augmentation: It stimulates T-cells and Natural Killer (NK) cells, boosting the body’s innate ability to identify and eliminate malignant cells. Anti-Angiogenesis: It prevents the formation of new blood vessels that tumors need to grow, effectively “starving“ the cancer cells. Cytokine Regulation: It reduces the production of pro-inflammatory cytokines like TNF-$alpha$ and IL-6, which otherwise foster a growth-friendly environment for tumors. Dosage and Administration Guidelines Standard Cycle: The typical dose is 4 mg once daily on Days 1–21 of a repeated 28-day cycle. Method of Intake: Swallow the capsule whole with water; do not crush, chew, or open the capsule. Consistency: It can be taken with or without food but should be taken at the same time every day. Blood Monitoring: Regular Complete Blood Counts (CBC) are mandatory to check for neutropenia or thrombocytopenia. Safety Profile and Clinical Precautions Hematological Risks: Common side effects include fatigue, fever, and a decrease in red/white blood cell counts. Thromboembolism: There is an increased risk of blood clots; physicians may prescribe blood thinners as a preventive measure. Pregnancy Warning: Pomalidomide is strictly contraindicated during pregnancy due to the high risk of birth defects. Strict contraception protocols are required for both men and women. Photosensitivity: The medication can make skin more sensitive to sunlight; protective clothing and sunscreen are advised. Storage and Handling Instructions Temperature: Store below 30°C in a cool, dry place. Protection: Keep capsules in the original blister packaging to protect from light and moisture. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Pomyelo 4mg Capsule is a high-potency immunomodulatory drug (IMiD) featuring the active pharmaceutical ingredient Pomalidomide. It is a third-generation thalidomide analogue specifically engineered to treat patients with complex hematological malignancies who have exhausted other treatment lines. Pomyelo represents a critical advancement in oncology, providing a powerful option for managing refractory diseases by leveraging the body's own immune system to target cancer. Therapeutic Indications and Clinical Usage Pomyelo 4mg is a primary choice in international oncology protocols for: Relapsed and Refractory Multiple Myeloma (RRMM): Indicated for adult patients who have received at least two prior therapies, including both Lenalidomide and a proteasome inhibitor (such as Bortezomib), and have demonstrated disease progression on or within 60 days of completion of the last therapy. Combination Therapy: For maximum clinical efficacy, Pomyelo is typically administered in combination with low-dose Dexamethasone. Kaposi Sarcoma (KS): Used for adult patients with AIDS-related Kaposi Sarcoma after failure of highly active antiretroviral therapy (HAART), or in HIV-negative patients with symptomatic disease. The Mechanism: How Pomyelo 4mg Works The active molecule, Pomalidomide, exerts its anti-cancer effects through a multi-faceted biological approach:Tumor Cell Inhibition: It directly binds to the protein Cereblon, part of an E3 ubiquitin ligase complex. This leads to the degradation of essential transcription factors (Aiolos and Ikaros), triggering apoptosis (programmed cell death) in myeloma cells.Immune System Modulation: It enhances the activity of T-cells and Natural Killer (NK) cells, empowering the body's natural defenses to identify and destroy malignant cells more aggressively.Anti-Angiogenesis: It blocks the development of new blood vessels that tumors rely on for oxygen and nutrients, effectively starving the cancer and preventing its spread.Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines like TNF-$alpha$ and Interleukin-6 (IL-6), which are known to fuel the growth of myeloma cells in the bone marrow microenvironment. Dosage and Administration Guidelines Standard Regimen: The recommended starting dose is 4mg orally once daily on Days 1–21 of repeated 28-day cycles. Cycle Management: Patients usually take the 4mg capsule at the same time each day for three weeks, followed by a 7-day rest period. Method of Intake: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Pomyelo can be taken with or without food. Monitoring: Treatment continues until disease progression or until a physician determines that the side effects outweigh the clinical benefits. Safety Profile and Professional Monitoring Clinical management of Pomyelo 4mg requires strict professional oversight to ensure patient safety: 1. Hematological Vigilance The most common side effects are neutropenia (low white blood cells), anemia, and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is a significantly increased risk of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). Patients are almost always prescribed prophylactic anticoagulants (like aspirin or heparin) concurrently with Pomyelo. 3. Embryo-Fetal Toxicity (REMS) Pomalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, constipation, diarrhea, and shortness of breath. Proactive management with supportive care is essential for maintaining treatment adherence. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Security: Keep capsules in the original blister pack to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the powder inside the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Inflitza 25mg Capsule (Midostaurin): Targeted Tyrosine Kinase Therapy for Hematologic Cancers Inflitza 25 mg Capsule is a potent anti-cancer medication featuring the active ingredient Midostaurin. As a multi-targeted tyrosine kinase inhibitor (TKI), it is specifically formulated to combat aggressive forms of blood cancer and rare hematological disorders. Manufactured by Intas Pharmaceuticals Ltd., a globally recognized leader in oncology, Inflitza 25mg represents a precision medicine approach—targeting specific genetic mutations and abnormal proteins that drive the progression of malignancy. Therapeutic Indications and Clinical Usage Inflitza 25 mg is a cornerstone treatment in global hematology protocols for: FLT3-Mutated Acute Myeloid Leukemia (AML): Indicated for adult patients with newly diagnosed AML who carry the FLT3 gene mutation. It is typically used in combination with standard induction (daunorubicin/cytarabine) and consolidation chemotherapy. Aggressive Systemic Mastocytosis (ASM): Targeted therapy for patients with this rare condition involving the accumulation of abnormal mast cells in organs like the liver, spleen, and bone marrow. Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN): Used to treat patients where mastocytosis occurs alongside other blood disorders. Mast Cell Leukemia (MCL): Prescribed for this highly aggressive form of leukemia to inhibit the rapid proliferation of malignant mast cells. Mechanism of Action: How Midostaurin Works Inflitza exerts its therapeutic effects by inhibiting several receptor tyrosine kinases: FLT3 Signaling Blockade: In AML, it targets the mutant FLT3 receptor, effectively cutting off the growth signals that allow leukemic cells to multiply uncontrollably. KIT Kinase Inhibition: In mast cell disorders, Midostaurin inhibits the KIT kinase (including the D816V mutation), which is critical for the survival and activation of abnormal mast cells. Induction of Apoptosis: By blocking these essential signaling pathways, Inflitza triggers programmed cell death (apoptosis) in malignant cells while sparing most healthy cells. Inhibition of Angiogenesis: It also interferes with the formation of new blood vessels that tumors require for nourishment and expansion. Dosage and Administration Guidelines Standard Dosing for AML: Usually 50 mg (two 25 mg capsules) taken orally twice daily on Days 8–21 of each chemotherapy cycle. Dosing for Mastocytosis: The typical dose is 100 mg (four 25 mg capsules) twice daily. Important Intake Rule: Inflitza must be taken with food to maximize absorption and reduce gastrointestinal irritation. Administration: Capsules should be swallowed whole with water. Do not open, crush, or chew the capsules. Safety Profile and Clinical Monitoring Due to its high potency, treatment with Inflitza 25mg requires strict medical supervision: 1. Gastrointestinal Support Nausea and vomiting are the most common side effects. Physicians often prescribe prophylactic antiemetics to be taken prior to the dose. 2. Hematological Vigilance Inflitza can cause febrile neutropenia (low white blood cells with fever). Frequent Complete Blood Counts (CBC) are required to monitor for potential infections. 3. Respiratory Monitoring There is a risk of lung inflammation (pneumonitis). Patients must report any new or worsening cough or shortness of breath immediately. 4. Heart and Liver Function Regular monitoring of heart rhythm (ECG) and liver function tests (LFTs) is standard practice to prevent complications like QT prolongation or hepatotoxicity. Storage and Global Handling Temperature: Store at room temperature, not exceeding 30°C. Protection: Keep capsules in their original blister packaging to protect from light and moisture. Shelf Life: 24 months from the date of manufacture. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Midostar 25mg Capsule (Midostaurin): Advanced Kinase Inhibitor for Hematologic Malignancies Midostar 25 mg Capsule is a sophisticated anti-cancer medication containing the active ingredient Midostaurin. It belongs to a specialized class of drugs known as multikinase inhibitors. Designed for precision oncology, Midostar targets specific proteins that signal cancer cells to grow and divide, making it a critical component in the treatment of Acute Myeloid Leukemia (AML) and various rare systemic mast cell disorders. Therapeutic Indications and Clinical Usage Midostar 25mg is extensively utilized across international oncology centers for: Acute Myeloid Leukemia (AML): Specifically indicated for newly diagnosed adult patients who test positive for the FLT3 mutation. It is used in combination with standard cytarabine and daunorubicin induction and high-dose cytarabine consolidation chemotherapy. Aggressive Systemic Mastocytosis (ASM): Targeted therapy for patients with this rare condition characterized by the accumulation of abnormal mast cells in organs. Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN): Used to manage complex cases where mastocytosis occurs alongside other blood cancers. Mast Cell Leukemia (MCL): Prescribed for this highly aggressive form of leukemia to inhibit the proliferation of malignant mast cells. The Mechanism: How Midostaurin Works Midostar exerts its therapeutic effects by inhibiting multiple receptor tyrosine kinases: FLT3 Inhibition: It blocks the mutant FLT3 receptor signaling, which is responsible for the rapid, uncontrolled proliferation of leukemic blasts in AML patients. KIT Receptor Targeting: By inhibiting wild-type and D816V mutant KIT kinases, Midostar effectively suppresses the survival and growth of abnormal mast cells. Broad Kinase Blockade: It also targets PDGFR (platelet-derived growth factor receptor) and several other kinases, disrupting the essential “growth signals“ cancer cells need to survive. Cell Cycle Arrest: The inhibition leads to programmed cell death (apoptosis) and prevents the spread of malignancy to other organs. Dosage and Administration Guidelines Dosing Schedule: For AML, the standard dose is 50 mg (two 25 mg capsules) twice daily (every 12 hours) on specific days of the chemotherapy cycle. Administration: Capsules must be swallowed whole with water. They should not be crushed, opened, or chewed. With Food: To reduce the risk of gastrointestinal distress, Midostar should always be taken with a meal. Renal and Hepatic Assessment: While generally stable, patients with severe hepatic or renal impairment require careful monitoring during therapy. Safety Profile and Patient Management As a potent targeted therapy, Midostar 25mg requires vigilant clinical monitoring: 1. Gastrointestinal Support Nausea and vomiting are common. Prophylactic antiemetic medications are often prescribed to ensure patient compliance and comfort. 2. Hematological Monitoring Commonly associated with febrile neutropenia (fever with low white blood cell count). Regular Complete Blood Counts (CBC) are mandatory to monitor for signs of infection. 3. Respiratory Vigilance Midostar may cause lung problems (interstitial lung disease/pneumonitis). Patients must report any new or worsening cough, shortness of breath, or chest pain immediately. 4. General Side Effects Other symptoms include musculoskeletal pain, headache, fatigue, and elevated blood sugar levels. Proper hydration and symptomatic management are standard clinical protocols. Storage and Handling Instructions Temperature: Store at room temperature, below 30°C (86°F). Protection: Keep capsules in their original blister packaging to protect them from moisture and light. Handling: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Mistaurin 25mg Capsule (Midostaurin): Advanced Kinase Inhibitor for Precision Hematology Mistaurin 25 mg Capsule is a high-efficacy, multi-targeted kinase inhibitor containing the active pharmaceutical ingredient Midostaurin. It is a breakthrough therapy in the field of hematology, specifically engineered to target malignant cells in patients with Acute Myeloid Leukemia (AML) and rare systemic mast cell disorders. By inhibiting the signaling pathways that drive cancer cell proliferation, Mistaurin has become a vital component of modern oncology protocols worldwide. Therapeutic Indications and Clinical Usage Mistaurin 25 mg is extensively utilized across international oncology centers for: FLT3-Mutation Positive AML: Indicated for newly diagnosed adult patients with Acute Myeloid Leukemia (AML) who are FLT3 mutation-positive, used in combination with standard induction and consolidation chemotherapy. Aggressive Systemic Mastocytosis (ASM): Targeted treatment for patients with this rare condition involving the overproduction of mast cells in the bone marrow and other organs. Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN): Used to manage complex cases where mastocytosis occurs alongside other blood cancers. Mast Cell Leukemia (MCL): Prescribed for this aggressive form of leukemia to inhibit the survival of malignant mast cells. Mechanism of Action: How Mistaurin 25mg Works Midostaurin, the active agent in Mistaurin, works by blocking several enzymes (kinases) on the surface and inside of cancer cells: FLT3 Receptor Inhibition: In AML, it targets the FLT3 receptor, which, when mutated, sends constant “grow“ signals to leukemic cells. KIT Kinase Targeting: In mast cell disorders, it inhibits the KIT receptor tyrosine kinase, which is responsible for the uncontrolled growth of mast cells. Broad Spectrum Blockade: It also inhibits other kinases like PDGFR and VEGFR, disrupting the essential signals cancer cells need to survive and build new blood vessels. Apoptosis Induction: By disrupting these signaling pathways, Mistaurin triggers programmed cell death (apoptosis) and effectively slows the progression of the disease. Dosage and Administration Guidelines Dosing for AML: The standard recommended dose is 50 mg (two 25 mg capsules) taken twice daily (every 12 hours) on specific days of the chemotherapy cycle. Administration: Capsules must be swallowed whole with a glass of water. They should not be crushed, chewed, or opened. With Food: Mistaurin should always be taken with food to minimize gastrointestinal side effects and improve absorption. Cycle Management: The duration of treatment is strictly determined by the treating oncologist based on the patient's clinical response and tolerability. Safety Profile and Professional Monitoring Treatment with Mistaurin 25 mg requires vigilant clinical oversight: 1. Gastrointestinal Management Nausea and vomiting are common. Doctors often prescribe anti-emetic medications before the dose to ensure patient comfort and adherence. 2. Respiratory Health Midostaurin may cause lung inflammation (interstitial lung disease). Patients should report any new or worsening cough or shortness of breath immediately. 3. Hematological Monitoring Common side effects include febrile neutropenia (low white blood cells with fever). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection risks. 4. Cardiac Vigilance In some cases, the drug may affect the heart's rhythm (QT prolongation). Periodic ECG monitoring may be recommended for certain patients. Storage and Handling Instructions Temperature: Store at room temperature, below 30°C (86°F). Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Mstarin 25mg Capsule (Midostaurin): Advanced Kinase Inhibitor for Precision Hematology Mstarin 25mg Capsule is a high-efficacy, multi-targeted kinase inhibitor containing the active pharmaceutical ingredient Midostaurin. It is a breakthrough therapy in the field of hematology, specifically engineered to target malignant cells in patients with Acute Myeloid Leukemia (AML) and rare systemic mast cell disorders. By inhibiting the signaling pathways that drive cancer cell proliferation, Mstarin has become a vital component of modern oncology protocols worldwide. Therapeutic Indications and Clinical Usage Mstarin 25mg is extensively utilized across international oncology centers for: FLT3-Mutation Positive AML: Indicated for newly diagnosed adult patients with Acute Myeloid Leukemia (AML) who are FLT3 mutation-positive, used in combination with standard induction and consolidation chemotherapy. Aggressive Systemic Mastocytosis (ASM): Targeted treatment for patients with this rare condition involving the overproduction of mast cells in the bone marrow and other organs. Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN): Used to manage complex cases where mastocytosis occurs alongside other blood cancers. Mast Cell Leukemia (MCL): Prescribed for this aggressive form of leukemia to inhibit the survival of malignant mast cells. Mechanism of Action: How Mstarin 25mg Works Midostaurin, the active agent in Mstarin, works by blocking several enzymes (kinases) on the surface and inside of cancer cells: FLT3 Receptor Inhibition: In AML, it targets the FLT3 receptor, which, when mutated, sends constant “grow“ signals to leukemic cells. KIT Kinase Targeting: In mast cell disorders, it inhibits the KIT receptor tyrosine kinase, which is responsible for the uncontrolled growth of mast cells. Broad Spectrum Blockade: It also inhibits other kinases like PDGFR and VEGFR, disrupting the essential signals cancer cells need to survive and build new blood vessels. Apoptosis Induction: By disrupting these signaling pathways, Mstarin triggers programmed cell death (apoptosis) and effectively slows the progression of the disease. Dosage and Administration Guidelines Dosing for AML: The standard recommended dose is 50mg (two 25mg capsules) taken twice daily (every 12 hours) on specific days of the chemotherapy cycle. Administration: Capsules must be swallowed whole with a glass of water. They should not be crushed, chewed, or opened. With Food: Mstarin should always be taken with food to minimize gastrointestinal side effects and improve absorption. Cycle Management: The duration of treatment is strictly determined by the treating oncologist based on the patient's clinical response and tolerability. Safety Profile and Professional Monitoring Treatment with Mstarin 25mg requires vigilant clinical oversight: 1. Gastrointestinal Management Nausea and vomiting are common. Doctors often prescribe anti-emetic medications before the dose to ensure patient comfort and adherence. 2. Respiratory Health Midostaurin may cause lung inflammation (interstitial lung disease). Patients should report any new or worsening cough or shortness of breath immediately. 3. Hematological Monitoring Common side effects include febrile neutropenia (low white blood cells with fever). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection risks. 4. Cardiac Vigilance In some cases, the drug may affect the heart's rhythm (QT prolongation). Periodic ECG monitoring may be recommended for certain patients. Storage and Handling Instructions Temperature: Store at room temperature, below 30°C (86°F). Security: Keep in the original blister pack to protect from moisture and light. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Staurinz 25mg Capsule (Midostaurin): Advanced Kinase Inhibitor for Precision Hematology Staurinz 25 mg Capsule is a high-efficacy, multi-targeted kinase inhibitor containing the active pharmaceutical ingredient Midostaurin. It is a breakthrough therapy in the field of hematology, specifically engineered to target malignant cells in patients with Acute Myeloid Leukemia (AML) and rare systemic mast cell disorders. By inhibiting the signaling pathways that drive cancer cell proliferation, Staurinz has become a vital component of modern oncology protocols worldwide. Therapeutic Indications and Clinical Usage Staurinz 25 mg is extensively utilized across international oncology centers for: FLT3-Mutation Positive AML: Indicated for newly diagnosed adult patients with Acute Myeloid Leukemia (AML) who are FLT3 mutation-positive, used in combination with standard induction and consolidation chemotherapy. Aggressive Systemic Mastocytosis (ASM): Targeted treatment for patients with this rare condition involving the overproduction of mast cells. Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN): Used to manage complex cases where mastocytosis occurs alongside other blood cancers. Mast Cell Leukemia (MCL): Prescribed for this aggressive form of leukemia to inhibit the survival of malignant mast cells. Mechanism of Action: How Staurinz 25mg Works Midostaurin, the active agent in Staurinz, works by blocking several enzymes (kinases) on the surface of cancer cells: FLT3 Receptor Inhibition: In AML, it targets the FLT3 receptor, which, when mutated, sends constant grow signals to leukemic cells. KIT Kinase Targeting: In mast cell disorders, it inhibits the KIT receptor tyrosine kinase, which is responsible for the uncontrolled growth of mast cells. Apoptosis Induction: By disrupting these signaling pathways, Staurinz triggers programmed cell death (apoptosis) and effectively slows the progression of the disease. Dosage and Administration Guidelines Dosing for AML: The standard recommended dose is 50 mg (two 25 mg capsules) taken twice daily on specific days of the chemotherapy cycle. Administration: Capsules must be swallowed whole with a glass of water. They should not be crushed, chewed, or opened. With Food: Staurinz should always be taken with food to minimize gastrointestinal side effects and improve absorption. Cycle Management: The duration of treatment is strictly determined by the treating oncologist based on the patient's clinical response and tolerability. Safety Profile and Professional Monitoring Treatment with Staurinz 25 mg requires vigilant clinical oversight: 1. Gastrointestinal Management Nausea and vomiting are common. Doctors often prescribe anti-emetic medications before the dose to ensure patient comfort. 2. Respiratory Health Tauritmo may cause lung inflammation (interstitial lung disease). Patients should report any new or worsening cough or shortness of breath immediately. 3. Hematological Monitoring Common side effects include febrile neutropenia (low white blood cells with fever). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection risks. 4. Cardiac Vigilance In some cases, the drug may affect the heart's rhythm (QT prolongation). Periodic ECG monitoring may be recommended for certain patients. Storage and Handling Instructions Temperature: Store at room temperature, below 30°C (86°C). Security: Keep in the original blister pack to protect from moisture and light. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Tauritmo 25mg Capsule (Midostaurin): Advanced Kinase Inhibitor for Hematologic Malignancies Tauritmo 25mg Capsule is a sophisticated anti-cancer medication containing the active ingredient Midostaurin. It belongs to a specialized class of drugs known as multikinase inhibitors. Designed for precision oncology, Tauritmo targets specific proteins that signal cancer cells to grow and divide, making it a critical component in the treatment of Acute Myeloid Leukemia (AML) and various rare systemic mast cell disorders. Therapeutic Indications and Clinical Usage Tauritmo 25mg is extensively utilized across international oncology centers for: Acute Myeloid Leukemia (AML): Specifically indicated for newly diagnosed adult patients who test positive for the FLT3 mutation. It is used in combination with standard cytarabine and daunorubicin induction and high-dose cytarabine consolidation chemotherapy. Aggressive Systemic Mastocytosis (ASM): Targeted therapy for patients with this rare condition characterized by the accumulation of abnormal mast cells in organs. Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN): Used to manage complex cases where mastocytosis occurs alongside other blood cancers. Mast Cell Leukemia (MCL): Prescribed for this highly aggressive form of leukemia to inhibit the proliferation of malignant mast cells. The Mechanism: How Midostaurin Works Tauritmo exerts its therapeutic effects by inhibiting multiple receptor tyrosine kinases: FLT3 Inhibition: It blocks the mutant FLT3 receptor signaling, which is responsible for the rapid, uncontrolled proliferation of leukemic blasts in AML patients. KIT Receptor Targeting: By inhibiting wild-type and D816V mutant KIT kinases, Tauritmo effectively suppresses the survival and growth of abnormal mast cells. Broad Kinase Blockade: It also targets PDGFR (platelet-derived growth factor receptor) and several other kinases, disrupting the essential “growth signals“ cancer cells need to survive. Cell Cycle Arrest: The inhibition leads to programmed cell death (apoptosis) and prevents the spread of malignancy to other organs. Dosage and Administration Guidelines Dosing Schedule: For AML, the standard dose is 50mg (two 25mg capsules) twice daily (every 12 hours) on specific days of the chemotherapy cycle. Administration: Capsules must be swallowed whole with water. They should not be crushed, opened, or chewed. With Food: To reduce the risk of gastrointestinal distress, Tauritmo should always be taken with a meal. Renal and Hepatic Assessment: While generally stable, patients with severe hepatic or renal impairment require careful monitoring during therapy. Safety Profile and Side Effect Management As a potent targeted therapy, Tauritmo 25mg requires vigilant clinical monitoring: 1. Gastrointestinal Support Nausea and vomiting are the most frequently reported side effects. Prophylactic anti-emetic medications are often prescribed to ensure patient compliance and comfort. 2. Hematological Monitoring Commonly associated with febrile neutropenia (fever with low white blood cell count). Regular Complete Blood Counts (CBC) are mandatory to monitor for signs of infection. 3. Respiratory Vigilance Tauritmo may cause lung problems (interstitial lung disease/pneumonitis). Patients must report any new or worsening cough, shortness of breath, or chest pain immediately. 4. General Side Effects Other symptoms include musculoskeletal pain, headache, fatigue, and elevated blood sugar levels. Proper hydration and symptomatic management are standard clinical protocols. Storage and Handling Instructions Temperature: Store at room temperature, below 30°C (86°F). Protection: Keep capsules in their original blister packaging to protect them from moisture and light. Handling: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Tepmetko 225mg Tablet (Tepotinib): Advanced Precision Therapy for METex14+ NSCLC Tepmetko 225 mg Tablet is a breakthrough oral precision medicine containing the active substance Tepotinib. It is a highly selective, once-daily MET (mesenchymal-epithelial transition) inhibitor specifically engineered to treat adult patients with metastatic Non-Small Cell Lung Cancer (NSCLC) that harbors MET exon 14 (METex14) skipping alterations. As the first oral MET inhibitor approved globally for this specific genetic driver, Tepmetko offers a targeted alternative to traditional chemotherapy, focusing directly on the molecular cause of tumor growth. Therapeutic Indications and Clinical Use Tepmetko 225mg is authorized for use across major international oncology centers for: Metastatic NSCLC (METex14+): Indicated for adult patients whose lung cancer has spread to other parts of the body and carries the METex14 skipping mutation. Treatment-Naïve & Previously Treated Patients: It is effective both as a first-line therapy and for patients whose cancer has progressed after receiving prior treatments such as immunotherapy or platinum-based chemotherapy. Advanced/Unresectable Disease: Utilized when the cancer is locally advanced and cannot be removed by surgery. The Mechanism: How Tepmetko 225mg Works Tepmetko belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Its action is highly specific: MET Pathway Inhibition: In certain lung cancers, the MET gene is mutated (METex14 skipping), causing the MET protein to stay “on“ and signal cells to divide uncontrollably. Targeted Blocking: Tepotinib attaches to the abnormal MET protein inside the cancer cells, effectively blocking the survival signals. Tumor Control: By inhibiting this pathway, Tepmetko slows or stops the growth and spread of the cancer, often leading to significant tumor shrinkage (objective response). Dosage and Administration Guidelines Standard Daily Dose: The recommended therapeutic dose is 450 mg, taken as two 225 mg tablets once daily. Method of Intake: Tablets must be swallowed whole with food to ensure optimal absorption. Do not chew, crush, or break the tablets. Dose Modifications: If a patient experiences intolerable side effects, an oncologist may reduce the dose to one 225 mg tablet daily or temporarily interrupt treatment. Missed Dose: If a dose is missed, it can be taken as soon as remembered on the same day, unless the next dose is due within 8 hours. Safety Profile and Professional Monitoring Treatment with Tepmetko 225 mg requires regular clinical supervision to manage the following: 1. Edema (Fluid Retention) The most common side effect (occurring in over 50% of patients) is peripheral edema, characterized by swelling in the ankles, feet, or hands. This is typically managed with salt restriction, leg elevation, or dose adjustments. 2. Interstitial Lung Disease (ILD) / Pneumonitis Though rare, Tepmetko can cause serious or life-threatening lung inflammation. Patients must immediately report new or worsening shortness of breath, cough, or fever. 3. Hepatotoxicity (Liver Health) Tepmetko may cause elevations in liver enzymes (ALT/AST). Liver function tests are mandatory before starting treatment and periodically throughout the therapy (every 2 weeks for the first 3 months). 4. Pancreatic Toxicity Elevations in amylase and lipase levels may occur. Monitoring of these levels is recommended to prevent pancreatic complications. 5. Common Side Effects Other frequently reported symptoms include fatigue, nausea, diarrhea, decreased appetite, and increased blood creatinine levels (a sign of kidney function changes). Storage and Global Handling Temperature: Store below 30°C (86°F) in a dry place. Original Packaging: Keep tablets in the original blister pack to protect them from moisture. Shelf Life: Typically has a shelf life of 30 months when stored correctly. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lynide 25 mg Capsule is a high-potency immunomodulatory drug (IMiD) containing the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, specifically designed to treat various plasma cell dyscrasias and complex blood cancers. Manufactured by Hetero Healthcare Ltd., a global leader in life-saving medications, Lynide 25mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Therapeutic Indications and Clinical Usage Lynide 25mg is extensively utilized across global oncology protocols for: Multiple Myeloma (MM): Used in combination with dexamethasone for patients with newly diagnosed multiple myeloma or those who have received at least one prior therapy. It is also a primary choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after two prior therapies, providing a vital line of defense. Follicular Lymphoma & Marginal Zone Lymphoma: Employed in combination with rituximab for previously treated patients to achieve better remission rates and progression-free survival. The Mechanism: How Lynide 25mg Works Lynide exerts its anti-cancer effects through a sophisticated multi-pathway mechanism: Immune Modulation: It enhances T-cell and Natural Killer (NK) cell-mediated immunity, significantly increasing the body's innate ability to identify and destroy malignant cells. Anti-Angiogenesis: It blocks the secretion of vascular endothelial growth factor (VEGF), effectively preventing the formation of new blood vessels that tumors need to survive and spread. Direct Cytotoxicity: It induces cell cycle arrest and apoptosis (programmed cell death) specifically in hematopoietic tumor cells. Anti-Inflammatory Action: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and various Interleukins (IL-1, IL-6, and IL-12). Dosage and Administration Guidelines Cycle-Based Dosing: Typically administered in 28-day cycles. For Multiple Myeloma, the standard dose is 25 mg taken orally once daily on Days 1–21, followed by a 7-day rest period. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: Can be taken with or without food, but should be taken at the same time each day to maintain steady therapeutic levels. Renal Monitoring: Since the drug is primarily excreted by the kidneys, dosage adjustments are strictly managed for patients with impaired renal function. Safety Profile and Side Effect Management Clinical management of Lynide 25mg requires vigilant professional oversight: 1. Hematological Support The most frequent side effects are neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular blood counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is an increased risk of blood clots (DVT or Pulmonary Embolism). Patients are often prescribed prophylactic anticoagulants (like aspirin or heparin) alongside Lynide. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are typically managed with supportive care and adequate hydration. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C. Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should avoid direct skin exposure to the powder inside the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenome 25 mg Capsule is a high-potency immunomodulatory drug (IMiD) containing the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, specifically designed to treat various plasma cell dyscrasias and complex blood cancers. As a structural analogue of thalidomide, Lenome 25mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Therapeutic Indications and Clinical Usage Lenome 25 mg is extensively utilized across global oncology protocols for: Multiple Myeloma (MM): Used in combination with dexamethasone for patients with newly diagnosed multiple myeloma or those who have received at least one prior therapy. It is also a primary choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after two prior therapies, providing a vital line of defense. Follicular Lymphoma & Marginal Zone Lymphoma: Employed in combination with rituximab for previously treated patients to achieve better remission rates and progression-free survival. The Mechanism: How Lenome 25mg Works Lenome exerts its anti-cancer effects through a sophisticated multi-pathway mechanism: Immune Modulation: It enhances T-cell and Natural Killer (NK) cell-mediated immunity, significantly increasing the body's innate ability to identify and destroy malignant cells. Anti-Angiogenesis: It blocks the secretion of vascular endothelial growth factor (VEGF), effectively preventing the formation of new blood vessels that tumors need to survive and spread. Direct Cytotoxicity: It induces cell cycle arrest and apoptosis (programmed cell death) specifically in hematopoietic tumor cells. Anti-Inflammatory Action: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and various Interleukins (IL-1, IL-6, and IL-12). Dosage and Administration Guidelines Cycle-Based Dosing: Typically administered in 28-day cycles. For multiple myeloma, the standard dose is 25 mg taken orally once daily on Days 1–21, followed by a 7-day rest period. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: Can be taken with or without food, but should be taken at the same time each day to maintain steady therapeutic levels. Renal Monitoring: Since the drug is primarily excreted by the kidneys, dosage adjustments are strictly managed for patients with impaired renal function. Safety Profile and Side Effect Management Clinical management of Lenome 25 mg requires vigilant professional oversight: 1. Hematological Support The most frequent side effects are neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular blood counts (CBC) are mandatory to monitor for infection or bleeding risks. If counts drop too low, a dose reduction or temporary pause is usually implemented. 2. Thromboembolism Prophylaxis There is a significantly increased risk of blood clots (DVT or Pulmonary Embolism). Patients are almost always prescribed prophylactic anticoagulants (like aspirin or heparin) alongside Lenome. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are typically managed with supportive care, adequate hydration, and symptomatic medication. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C. Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should wear gloves if handling the capsules directly to avoid accidental skin exposure to the active powder. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenmid 25mg Capsule is a high-potency immunomodulatory drug (IMiD) containing the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, specifically designed to treat various plasma cell dyscrasias and complex blood cancers. Manufactured by Cipla Ltd., a global pharmaceutical leader, Lenmid 25mg is recognized for its high efficacy, safety standards, and role in extending survival rates for patients worldwide. Therapeutic Indications and Clinical Usage Lenalidomide 25 mg is extensively utilized across international oncology protocols for: Multiple Myeloma (MM): Used in combination with dexamethasone for newly diagnosed patients or those who have failed at least one prior therapy. It is also the gold standard for maintenance therapy post-autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically indicated for transfusion-dependent anemia caused by low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after two prior therapies. Follicular & Marginal Zone Lymphoma: Often used in combination with Rituximab for patients previously treated for these indolent lymphomas. Mechanism of Action: How Lenmid 25mg Works Lenmid exerts its anti-cancer effects through a multi-faceted biological approach: Direct Cytotoxicity: It binds to the cereblon E3 ubiquitin ligase complex, leading to the degradation of essential transcription factors, which triggers apoptosis (programmed cell death) in malignant cells. Immune System Enhancement: It stimulates the production of Interleukin-2 (IL-2) and Interferon-gamma (IFN-$gamma$), which enhances the activity of T-cells and Natural Killer (NK) cells to actively destroy tumors. Anti-Angiogenesis: It blocks the secretion of pro-angiogenic factors like VEGF, effectively starving the tumor of the blood supply it needs to grow. Anti-Inflammatory Action: It reduces the production of pro-inflammatory cytokines such as TNF-$alpha$, altering the bone marrow microenvironment to make it less hospitable for cancer cells. Dosage and Administration Guidelines Standard Regimen: Typically administered in 28-day cycles. In multiple myeloma, the standard dose is 25 mg taken orally once daily on Days 1–21, followed by a 7-day break. Method of Intake: Capsules must be swallowed whole with water. They should not be crushed, opened, or chewed. Timing: Can be taken with or without food, but should be taken at the same time every day to maintain consistent blood levels. Renal Monitoring: Since Lenalidomide is primarily excreted by the kidneys, dosage adjustments are vital for patients with impaired renal function. Safety Profile and Side Effect Management Clinical management of Lenmid 25mg involves proactive monitoring of the following: 1. Hematological Support Common side effects include neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are mandatory. If counts drop significantly, a dose reduction or temporary treatment interruption is standard practice. 2. Thromboembolism Prophylaxis Patients taking Lenmid have an increased risk of venous thromboembolism (blood clots). Standard care involves prescribing prophylactic anticoagulants (like aspirin or heparin) concurrently with the medication. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is structurally related to thalidomide and is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients of reproductive potential. 4. General Side Effects Patients may report fatigue, diarrhea, muscle cramps, or skin rashes. These are typically managed through adequate hydration, supportive care, and symptomatic medication. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Security: Keep in the original blister pack to protect from light and moisture. Handling: Caregivers should handle capsules with care and avoid direct skin contact with the powder inside Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383